Cargando…

OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices

BACKGROUND: Primary aldosteronism (PA) is broadly divided into unilateral and bilateral forms, and the most reliable subtyping tool available is adrenal vein sampling (AVS). Unilateral PA is generally diagnosed based on AVS lateralization indices (LI=[aldosterone/cortisol] ratio between the dominant...

Descripción completa

Detalles Bibliográficos
Autores principales: Giordano, Thomas, Konzen, Sonja, Rainey, William, Salman, Zara, Tezuka, Yuta, Udager, Aaron, Turcu, Adina F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629361/
http://dx.doi.org/10.1210/jendso/bvac150.514
_version_ 1784823382691282944
author Giordano, Thomas
Konzen, Sonja
Rainey, William
Salman, Zara
Tezuka, Yuta
Udager, Aaron
Turcu, Adina F
author_facet Giordano, Thomas
Konzen, Sonja
Rainey, William
Salman, Zara
Tezuka, Yuta
Udager, Aaron
Turcu, Adina F
author_sort Giordano, Thomas
collection PubMed
description BACKGROUND: Primary aldosteronism (PA) is broadly divided into unilateral and bilateral forms, and the most reliable subtyping tool available is adrenal vein sampling (AVS). Unilateral PA is generally diagnosed based on AVS lateralization indices (LI=[aldosterone/cortisol] ratio between the dominant and contralateral adrenal vein) ≥4, or even ≥2 when AVS is performed without cosyntopin stimulation. Long-term follow-up data from patients with PA treated with unilateral adrenalectomy have been minimal. OBJECTIVE: To assess the rates of residual and recurrent PA after AVS-guided unilateral adrenalectomy. METHODS: We enrolled patients with PA who underwent unilateral adrenalectomy between 09/2017 and 08/2021 in a single tertiary referral center and followed them longitudinally. Demographics, laboratory, imaging, and pathology data were collected. Aldosterone synthase (CYP11B2) immunohistochemistry and next generation sequencing were performed on available formalin-fixed paraffin-embedded adrenal tissue blocks. RESULTS: During the study period, 80 patients (52 men) with median age 53 (range, 19-76) years underwent unilateral adenectomy, and were followed for a median 80 days (range, 6-653 days). In total 14 (17.5%) patients had evidence of residual PA following surgery, including 3 who had complete biochemical failure, and 1 who had apparent cure of PA immediately post-operatively. All 14 patients had severe PA, with baseline plasma aldosterone concentrations between 23.4 and 496 ng/dL and suppressed renin. Baseline and post-cosyntropin stimulation LIs ranged from 2.7- 187.5 and 1.3-53.7. The LI was >4 only at baseline in 3 cases, and only after cosyntropin stimulation in 2 cases. Histology showed single adenomas, ranging from 0.7-5.3 cm in 7 (50%) patients, and multiple adenomas and/or nodular hyperplasia in 7 (50%) patients. Of the 7 cases analyzed for aldosterone-driver mutations so far, 4 harbored CACNA1D mutations, 2 ATP1A1 mutations, and 1 a KCNJ5 mutation. CONCLUSIONS: Patients with severe PA and frank AVS aldosterone lateralization might have multifocal, bilateral disease. Long-term follow up and targeted medical therapy should be pursued after unilateral adrenalectomy for presumed unilateral PA. Presentation: Monday, June 13, 2022 11:15 a.m. - 11:30 a.m.
format Online
Article
Text
id pubmed-9629361
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96293612022-11-04 OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices Giordano, Thomas Konzen, Sonja Rainey, William Salman, Zara Tezuka, Yuta Udager, Aaron Turcu, Adina F J Endocr Soc Cardiovascular Endocrinology BACKGROUND: Primary aldosteronism (PA) is broadly divided into unilateral and bilateral forms, and the most reliable subtyping tool available is adrenal vein sampling (AVS). Unilateral PA is generally diagnosed based on AVS lateralization indices (LI=[aldosterone/cortisol] ratio between the dominant and contralateral adrenal vein) ≥4, or even ≥2 when AVS is performed without cosyntopin stimulation. Long-term follow-up data from patients with PA treated with unilateral adrenalectomy have been minimal. OBJECTIVE: To assess the rates of residual and recurrent PA after AVS-guided unilateral adrenalectomy. METHODS: We enrolled patients with PA who underwent unilateral adrenalectomy between 09/2017 and 08/2021 in a single tertiary referral center and followed them longitudinally. Demographics, laboratory, imaging, and pathology data were collected. Aldosterone synthase (CYP11B2) immunohistochemistry and next generation sequencing were performed on available formalin-fixed paraffin-embedded adrenal tissue blocks. RESULTS: During the study period, 80 patients (52 men) with median age 53 (range, 19-76) years underwent unilateral adenectomy, and were followed for a median 80 days (range, 6-653 days). In total 14 (17.5%) patients had evidence of residual PA following surgery, including 3 who had complete biochemical failure, and 1 who had apparent cure of PA immediately post-operatively. All 14 patients had severe PA, with baseline plasma aldosterone concentrations between 23.4 and 496 ng/dL and suppressed renin. Baseline and post-cosyntropin stimulation LIs ranged from 2.7- 187.5 and 1.3-53.7. The LI was >4 only at baseline in 3 cases, and only after cosyntropin stimulation in 2 cases. Histology showed single adenomas, ranging from 0.7-5.3 cm in 7 (50%) patients, and multiple adenomas and/or nodular hyperplasia in 7 (50%) patients. Of the 7 cases analyzed for aldosterone-driver mutations so far, 4 harbored CACNA1D mutations, 2 ATP1A1 mutations, and 1 a KCNJ5 mutation. CONCLUSIONS: Patients with severe PA and frank AVS aldosterone lateralization might have multifocal, bilateral disease. Long-term follow up and targeted medical therapy should be pursued after unilateral adrenalectomy for presumed unilateral PA. Presentation: Monday, June 13, 2022 11:15 a.m. - 11:30 a.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9629361/ http://dx.doi.org/10.1210/jendso/bvac150.514 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Giordano, Thomas
Konzen, Sonja
Rainey, William
Salman, Zara
Tezuka, Yuta
Udager, Aaron
Turcu, Adina F
OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
title OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
title_full OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
title_fullStr OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
title_full_unstemmed OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
title_short OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
title_sort or20-2 bilateral primary aldosteronism is not excluded by high adrenal vein sampling lateralization indices
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629361/
http://dx.doi.org/10.1210/jendso/bvac150.514
work_keys_str_mv AT giordanothomas or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices
AT konzensonja or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices
AT raineywilliam or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices
AT salmanzara or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices
AT tezukayuta or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices
AT udageraaron or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices
AT turcuadinaf or202bilateralprimaryaldosteronismisnotexcludedbyhighadrenalveinsamplinglateralizationindices